PI3K/Akt/mTOR Signaling Pathway as a Target for Colorectal Cancer Treatment
Open accessThe DOI matches its Crossref record; 143 of the 144 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
In the last decade, pathway-specific targeted therapy has revolutionized colorectal cancer (CRC) treatment strategies. This type of therapy targets a tumor-vulnerable spot formed primarily due to an alteration in an oncogene and/or a tumor suppressor gene. However, tumor heterogeneity in CRC frequently results in treatment resistance, underscoring the need to understand the molecular mechanisms involved in CRC for the development of novel targeted therapies. The phosphatidylinositol 3-kinase/protein kinase B/mammalian target of the rapamycin (PI3K/Akt/mTOR) signaling pathway axis is a major pathway altered in CRC. The aberrant activation of this pathway is associated with CRC initiation, progression, and metastasis and is critical for the development of drug resistance in CRC. Several drugs target PI3K/Akt/mTOR in clinical trials, alone or in combination, for the treatment of CRC. This review aims to provide an overview of the role of the PI3K/Akt/mTOR signaling pathway axis in driving CRC, existing PI3K/Akt/mTOR-targeted agents against CRC, their limitations, and future trends.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Activating mutations in PIK3CA can also contribute to resistance to anti-EGFR therapy in KRAS-WT CRC patients by persistent activation of the PI3K/AKT/mTOR signaling pathway [126].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“While PI3K pathway inhibitors as a monotherapy have not shown significant antitumor effects in treating CRC, their utility in combination therapy is actively being studied.”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
The cited source says what the claim attributes to it.
In the citing paper
“Various drugs targeting this pathway are under investigation for CRC treatment, including pan-PI3K inhibitors, isoform-specific PI3K inhibitors, dual PI3K-mTOR inhibitors, Akt inhibitors, and mTOR inhibitors [126].”
From Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer (2025) · cites this paper as [126]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Repertoires of Autophagy in the Pathogenesis of Ocular Diseases
Li, Y.-J., Jiang, Q., Cao, G.-F., Yao, J., & Yan, B. (2015) · Cellular Physiology and Biochemistry · doi:10.1159/000373980 · Cited by 16,304
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216 · cited 2×
“…in both the cytoplasm and nucleus, including the Bcl2-associated agonist of cell death (BAD), forkhead box O (FOXO), glycogen synthase kinase 3 (GSK3), the Full Akt activity is achieved through phosphorylation at the Serine 473 residue in the C-terminal hydrophobic motif by mTORC2 [17].”
BackgroundAKT/PKB signaling: navigating downstream
Manning, B. D., & Cantley, L. C. (2007) · Cell · doi:10.1016/j.cell.2007.06.009 · Cited by 6,115
mTOR: from growth signal integration to cancer, diabetes and ageing
Zoncu, R., Efeyan, A., & Sabatini, D. M. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3025 · Cited by 3,941 · cited 4×
“Compared with other PI3K pathway inhibitors, dual PI3K/mTOR inhibitors can inhibit all PI3K catalytic isoforms, mTORC1, and mTORC2 [80] and should block this pathway completely and overcome the feedback inhibition observed with mTORC1 inhibitors (i.e., rapamycin analogs).”
BackgroundInfluentialColorectal cancer statistics, 2023
Siegel, R. L., Wagle, N. S., Cercek, A., Smith, R. A., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21772 · Cited by 3,733
High Frequency of Mutations of the PIK3CA Gene in Human Cancers
Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., et al. (2004) · Science · doi:10.1126/science.1096502 · Cited by 3,437
Alessi, D. R., James, S. R., Downes, C. P., Holmes, A. B., Gaffney, P. R. J., Reese, C. B., & Cohen, P. (1997) · Current Biology · doi:10.1016/s0960-9822(06)00122-9 · Cited by 2,826
The PI3K Pathway in Human Disease
Fruman, D. A., Chiu, H., Hopkins, B. D., Bagrodia, S., Cantley, L. C., & Abraham, R. T. (2017) · Cell · doi:10.1016/j.cell.2017.07.029 · Cited by 2,749 · cited 5×
“The PI3K/Akt/mTOR pathway axis is critical for cell survival, proliferation, and growth, and it is one of the most frequently altered pathways in human cancer, making it a promising target for cancer therapy [9–12].”
BackgroundInfluential
Cited by
Items 101–194 of 194
Yan, S., Lan, T., Wang, H., Wang, N., Hou, Q., Luan, Y., Shi, Y., Hu, S., Gong, X., & Song, Y. (2025) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b25-00188 · Cited by 1
PI3Kα inhibitors: structural advances, synthesis strategies, and anticancer potential
Swati, Kumar, S., Chander, S., Wadhwa, P. K., Ghnaim, A. O., Bhandare, R. R., & SHAIK, A. B. (2025) · Journal of Saudi Chemical Society · doi:10.1007/s44442-025-00047-5 · Cited by 1
Vieira, L. M., Jorge, N. A. N., de Sousa, J. B., Setúbal, J. C., Stadler, P. F., & Walter, M. E. M. T. (2025) · Oncotarget · doi:10.18632/oncotarget.28783 · Cited by 1
Clinicopathological significance of common PIK3CA exon mutations in non-metastatic colorectal cancer
Chen, J.-X., Song, X.-H., Yang, X., Zhang, X.-E., Wu, Y.-X., Chen, G.-M., Wang, J.-Q., Ding, Y.-H., & Chen, J.-S. (2025) · Future Oncology · doi:10.1080/14796694.2025.2600907 · Cited by 2
Gu, F., Chen, Z., Lim, X., Zhang, T., Yuan, J., & Li, L. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s574142 · Cited by 2
A marine-derived meroterpenoid inhibits colorectal cancer via PI3K pathway modulation in mice
Han, M.-Q., Zhang, J.-C., Zhao, Y.-J., Liu, Y.-F., Zhu, H., Pittman, C. U., & Cao, F. (2026) · Marine Life Science & Technology · doi:10.1007/s42995-026-00356-7 · Cited by 1
Zeng, X., Li, Y., Wang, X., Luo, X., Wang, C., Li, Z., Bai, Q., 陈胜华, & Chen, L. (2026) · Microbial Pathogenesis · doi:10.1016/j.micpath.2026.108442 · Cited by 1
Bhalani, S., Parmar, P., Modasiya, I. J., Padhi, A., & Agarwal, A. (2026) · VirusDisease · doi:10.1007/s13337-026-00964-y · Cited by 1
Guo, L., zhao, W., Wang, H., 邱書璇, Wang, R., 张景亚, Tian, S., & Miao, M. S. (2026) · Drug Design Development and Therapy · doi:10.2147/dddt.s564320 · Cited by 1
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Shi, Q., Zhou, T., Zhou, Y., Wang, Z., Xue, Y.-J., & Chen, Y. (2025) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2025.118203 · Cited by 1
Deng, R., Wang, M., Promlek, T., Druelle-Cedano, C., Murad, R., Davidson, N., & Kaufman, R. J. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.01.651751 · Cited by 1
Liu, Z., Ang, M. Y., & Kue, C. S. (2026) · doi:10.2196/preprints.95204 · Cited by 1
Hwangbo, H., & Choi, Y. H. (2024) · Journal of the Korean Society of Food Science and Nutrition · doi:10.3746/jkfn.2024.53.10.1021
Liu, Y., Huang, M., Tian, X., & Huang, X. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040267 · Cited by 2
Kumar, R., He, Y., Zhou, J., Beggs, A. D., & Gendoo, D. M. A. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.10.648131
Mutra, R., & Vallabhapurapu, S. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.05.12.653423
Postbiotics and Metabolic Signaling in Colorectal Cancer
Ahamad, R., Uthumansha, U., Anjum, S., Khan, Z., Sagavkar, S. R., Dash, S., Taj, T., Kumar, S., Mollick, M., & Ashique, S. (2025) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-031-86065-2_4
Zhang, H., Liu, Y., Wang, J., wang, S., Xue, G., Zhi, Y., Miao, M., Fang, X., Wu, J., Wang, H., et al. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5323846
Biological effects and mechanism of RAW246.7 cells exposed to hexavalent uranium
Ming, H., Yan, Z., Li, H., Liang, J., Liu, L., & Song, W. (2025) · Environmental Toxicology and Chemistry · doi:10.1093/etojnl/vgaf197
Extracellular Vesicle Gene Expression Enables Sensitive Detection of Colorectal NeoplasiaPreprint
Gowrisankar, S., Ray, J. C. J., Nguyen, S., Benway, C. J., Xing, S., George, A., Miller, D. L., Manning, K., Yang, Y., Cole, T. J., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.08.14.670394
Moazed, K. T. (2025) · Springer eBooks · doi:10.1007/978-3-032-05044-1_1 · Cited by 2
Relationship between uric acid and colon cancer risk: Dose-response analysis and mechanisms
Sun, T.-F., Fan, K.-X., Luo, Y.-X., Song, J., Han, Z., & Zhang, X. (2025) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v17.i9.107651
Ye, Y., Su, T., Gao, J., & Ming, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189004
“Are et al. [27] mTOR signaling pathway Directly acts on the mTOR signaling pathway, inhibiting the activity of mTORC1 and mTORC2, thereby inhibiting tumor cell growth and proliferation.”
Mao, J., Gai, Q., Bao, X., & Zhong, M. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1651236 · Cited by 3
Chang, Y., Liu, Y., Hao, Y., Guo, J., Bai, K., Huang, F., & Hu, Y. (2025) · Research Square · doi:10.21203/rs.3.rs-7724776/v1 · Cited by 1
Yao, A., Li, G., Gu, X., Cao, L., & Zheng, P. (2025) · Molecular & Cellular Toxicology · doi:10.1007/s13273-025-00584-5
Wang, X., Zhang, C.-A., & Ye, M. (2025) · Medicine · doi:10.1097/md.0000000000045358
Zhu, D., Chen, P., Yu, L., Gao, S., Liu, Y., Pan, S., & Li, L. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110993
Colorectal Cancer Pathogenesis and Treatment Strategies: Insights into the Role of p53
Kordkatouli, M., Heidari, M., Azami, N., & Poursamimi, J. (2025) · Multidisciplinary Cancer Investigation · doi:10.61882/mci.8.2.1 · Cited by 1
Liang, X., Yao, J., Jiao, W., Li, X., Yang, B., & Fan, H. (2025) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-025-05992-3 · Cited by 1
Multi-omics integration and network analysis identify therapeutic hub genes in colorectal cancer
Mathew, E., Thomas, P. L. L., & Mathew, L. (2025) · Network Modeling Analysis in Health Informatics and Bioinformatics · doi:10.1007/s13721-025-00696-x
Yin, Y., Li, X., Xie, Y., Liu, S., Tan, S., & Xu, C. (2026) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-026-01091-6
Effect of Natural Products in the Prevention and Treatment of Colorectal Cancer
Hassan, E. S., Abdulateef, D. S., Ahmed, F. N., Mohammed, G. A., & Rahman, H. S. (2026) · Indian Journal of Medical and Paediatric Oncology · doi:10.1055/s-0046-1816066
Yavari, F., Giv, N. H., Mohajerani, F., Givi, T., Soltaninejad, H., Mohammadzade-Asl, A., & Sadeghizadeh, M. (2026) · Research Square · doi:10.21203/rs.3.rs-8492371/v1
Yilmaz, Z. S., Keçeci, S. D., Sağol, Ö., & Sarıoğlu, S. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48020179
Gebhart, A. R., Berns, M. M. M., Snoeys, J., Elassaiss‐Schaap, J., & de Lange, E. C. M. (2026) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00622-x
Sulforaphane Attenuates Methamphetamine‐Induced Neurotoxicity via Activation of the PI3K/AKT Pathway
Li, S., Zhang, J., Li, X., Zhang, G., Ren, L., Yang, C., Niu, S., Wen, C., Wang, Y., & Yan, J. (2026) · Journal of Biochemical and Molecular Toxicology · doi:10.1002/jbt.70769
P62 in colorectal cancer: from inflammation suppression to cancer promotion
Niumuqie, A., Huang, J., Liu, L., Chen, H., Chen, J., Zou, S., Pang, Y., Wu, X., Liu, M., & Liang, G. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1760631 · Cited by 2
Effekt von niedrig dosierter Acetylsalicylsäure auf Rezidivrisiko – ALASCCA-Studie
Horr, F., & Quante, M. (2026) · Gastro-News · doi:10.1007/s15036-026-4006-2
Lin, H., Jia, B., Chang, B., Sun, F., Tan, Y., Tian, Y., Fan, Y., Liang, J., & Wu, A. W. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c15968
Patel, H., Li, Y., Chen, X. Y., Chen, X., Wu, Z., Patel, S., Chen, Z., & Tang, H. (2026) · Cancer Genetics · doi:10.1016/j.cancergen.2026.04.002
Ravi, A. M. M. (2026) · International Journal of Biosciences (IJB) · doi:10.12692/ijb/28.3.22-32
Luo, J., Luo, J., Huang, Y., Lei, Q., Wu, Y., Han, B., & Xu, B. (2026) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.5c17741
Zheng, Z., Hou, X., Li, W., & Zhang, L. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48040342
Wu, X.-F., Xie, L.-Y., Lian, F.-W., Wei, H., Ning, S., & Hu, B.-L. (2026) · Functional & Integrative Genomics · doi:10.1007/s10142-026-01868-2
Khanaree, C., Inpan, R., Taychaworaditsakul, W., & Dukaew, N. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27093874
Throat, S., Bhattacharya, S., Beldar, V., Sangave, P. C., Sharma, S., Khan, R., Saoji, S. D., & Joshi, A. (2026) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2026.2661848 · Cited by 2
Sharif-zak, M., Sadeghloo, Z., Binayi, F., Nobili, S., Ashtari, S., Sadeghi, A., & Fatemi, N. (2026) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.71137
Advances in regulatory mechanisms of glycolysis in the pathological process of pulmonary fibrosis
Gao, F., Pu, R., Pan, G., Ma, Y., Zhao, J., Ruohui, W., Cao, X., & Liang, Q. (2026) · European journal of medical research · doi:10.1186/s40001-026-04423-8 · Cited by 1
Wang, S., Yang, G., Zhang, Q., & Zhang, Y. (2026) · European Journal of Histochemistry · doi:10.4081/ejh.2026.4544
Zhao, J., Zhang, X., Chen, Y. N., Zhou, M., Pan, Z., Ni, M., Li, S., Chen, X., & Xie, L. (2026) · Veterinary and Animal Science · doi:10.1016/j.vas.2026.100708
Wu, X., Li, J., Zhang, X., Huang, H., Li, T., Kong, M., Dai, Z., Yang, Y., & Chen, X. (2026) · Journal of Ovarian Research · doi:10.1186/s13048-026-02146-2
Dehydrocorydaline Exerts Anti-Pancreatic Cancer Effects Through the PI3K/Akt/mTOR Pathway
Yu, Q., Li, R., Li, Z., Wan, Z., Lv, K., He, C., Sun, J., Jia, S., Xu, Y., & Zhao, M. (2026) · Pharmaceuticals · doi:10.3390/ph19060864
Bai, Q., Wu, C., Linna, S., Li, N., Tan, J., & Li, Q. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121175
Aguiari, G., Bianchi, N., & Franzese, O. (2026) · Cells · doi:10.3390/cells15121074
Akshatha, S., & Eligar, S. M. (2026) · Applied Biochemistry and Biotechnology · doi:10.1007/s12010-026-05785-9
Regulatory effects of luteolin on apoptosis and autophagy in lung cancer A549 cells
Gu, K., Zhang, C.-Y., Hao, D., Chi, M.-Y., Li, T., Bai, C., & Gao, X. (2026) · Journal of Toxicology and Environmental Health · doi:10.1080/15287394.2026.2693493
Jeon, J., Jang, J., Moon, C. Y., Lee, J., Hong, V. S., Kang, H., Park, J. T., Heo, N. H., Park, J. T., Park, J., et al. (2026) · Pharmaceuticals · doi:10.3390/ph19070985
Ramos-Silva, J. A., Lara-Hernández, G., Fuentes-Garibay, J. A., Pérez-Soto, E., Flores-Berrios, E. P., & Avilés‐Arnaut, H. (2026) · Molecules · doi:10.3390/molecules31142414
Khan, M. M., Hossain, M. A., Hossain, M. S., Gupta, D. D., Showrov, N. A., & Parvin, S. (2026) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2026.111854
Cancer Signaling Pathways and Cancer Biology
Nair, A., Prasad, A. P., Anand, A. V., Shyl, D., & Yesupatham, S. K. (2026) · Studies in Rhythm Engineering · doi:10.1007/978-981-95-8938-8_7
Yang, F., Yu, H., Ni, J., Sun, Y., Zhu, X., Wang, H., Zhao, X., & Zhao, B. (2026) · Molecular and Cellular Biology · doi:10.1080/10985549.2026.2685572
Tang, B., Li, K., Chen, W., Xiao, J., Duan, Q., & Zhu, F. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1857616
Vass, A., Király, J., Szabó, E., Kónya, G., Shammas, A., Szegedi, K., Dezsö, B., Juhász, É., Halmos, G., & Szabó, Z. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48070739
Cui, Q., Gao, X., Wu, X., & Zhang, D. (2026) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2026.1874138 · Cited by 2
ZNF556 serves as an immunological and prognostic biomarker in colon adenocacinoma
Huang, C., Feng, S., Yi, H., Tao, W., Li, Y., & Liao, Z. (2026) · BMC Cancer · doi:10.1186/s12885-026-16596-w
UBC9 and PI3K Expression in Colorectal Cancer: Possible Prognostic Role
Nasser, O., Rabea, A., & Diaa, R. (2026) · Apmis · doi:10.1111/apm.70242
Application of Systems Genetics to Investigate Molecular Pathology of Early‐Onset Colorectal Cancer
Kim, M. J., Carr, S. L., Kulkarni, V., & Manchadi, M. (2026) · Chemical Biology & Drug Design · doi:10.1111/cbdd.70379
Zhou, K., Lu, P., Xu, H., & Liang, X. (2026) · Journal of Immunology Research · doi:10.1155/jimr/5084171 · Cited by 1
An, N., Liu, Q., Tian, J., Fan, X., Li, H., Shan, S., Shi, J., & Li, Z. (2026) · Foods · doi:10.3390/foods15162834
Li, J., Jiang, K., Wang, S., Cai, Y., Shang, L., Zhou, F., Wang, Y., Huang, J., Hu, S., Yan, Q., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1813778
Qian, L., & Weng, X. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100530
Das, S. R., Koman, I. E., & Nesher, E. (2026) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2026.08.003
Yumrutaş, Ö., Rios, M., Yumrutaş, P., Korkmaz, M., Escobar, J., Parlar, A., & Martínez, J. L. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27167420
kaikavoosnejad, F., Kashani, H., Asl, K. D., Mazloumi, Z., Keyhani, A., Moosavi, S. S., Verdi, M., & Rafat, A. (2026) · Medical Oncology · doi:10.1007/s12032-026-03374-8 · Cited by 1
Li, L., Yang, D., Yan, Y., Hu, W., Jiang, Y., Liu, P., Shi, Y., & Bai, Y. (2026) · Research Square · doi:10.21203/rs.3.rs-10721594/v1
Zhu, L., Liang, Y., Mao, Q., & Zhang, J. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189699
Alsubeeh, K., Yaltir, A., Yalın, A. E., Ünal, N., & Yalın, S. (2026) · Nucleosides Nucleotides & Nucleic Acids · doi:10.1080/15257770.2026.2735915
Zhang, Y., Ding, N., Cui, Y., Yi, C., & Chen, W. (2026) · Frontiers in Oncology · doi:10.3389/fonc.2026.1945549
CSN3 promotes colorectal cancer cell progression through activation of the PI3K/AKT/mTOR pathway
Chen, C., Tu, T., Xu, H., Wang, G., Lu, Y., & Huang, G. (2026) · Molecular Biology Reports · doi:10.1007/s11033-026-12825-4
Wan, K., Tang, K., Wang, L., Tian, Q., Zheng, M., Qian, C., & 刘丽梅 (2026) · MedComm · doi:10.1002/mco2.71028
Expression of COL6A1 in Tumor Matrix of Cholangiocarcinoma and Its Mechanism of Tumor Progression
zhang, W., Gao, C., Lan, C., Dong, J., Xu, B., Li, Y., Jin, D., Che, B., Li, C., Dong, G., et al. (2026) · Cancer Reports · doi:10.1002/cnr2.70716
Zhou, S., Xiang, T., Cha, Z., Song, J., Xiang, Y., Li, X., Huang, C., Mei, Q., Huang, X., Zhang, C., et al. (2026) · Analytical Chemistry · doi:10.1021/acs.analchem.6c04145
Colitis-associated colorectal carcinogenesis: molecular mechanisms and therapeutic potential
Lu, Y., Wang, X., Yin, C., Wang, J., Guo, S., Wang, Z., Zhou, J., Cui, M., Cheng, X., Zhang, L., et al. (2026) · Molecular Biomedicine · doi:10.1186/s43556-026-00623-0
Ramachandran, P., Chen, C. S. Y., Lee, C. S., Aye, T. T., Kunjukunju, A., Elias, M. H., Mydin, A. R., & Low, T. Y. (2026) · Expert Review of Proteomics · doi:10.1080/14789450.2026.2750129
Gao, J.-M., Yan, W., Yang, J., Ren, H., Zhao, L., Zhang, Y., Chen, Y., Zhou, J., Wei, Z.-Z., Liu, Q., et al. (2026) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2026.129000
Pascu, A., Ianole, V., & Danciu, M. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27209346
Shi, C., Chen, Y., Hu, X., Jin, F., Liu, Q., Ou, C., & Lu, Y. (2026) · Asia-Pacific Journal of Clinical Oncology · doi:10.1111/ajco.70200
Ranjbar, M., Maghsodiyan, S., Khakdan, F., & Bayram, M. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.179464
Ibrahim, D., Khater, S. I., Abdelfattah‐Hassan, A., Babteen, N. A., Alqahtani, L. S., Qahl, S. H., Mostafa, M., El-Shaer, N. O., Abdel-Raheem, S. M., Alkhayyal, N., et al. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1963760
Perera, R. M. T. D., KIM, S.-L., Kim, J.-H., Kim, K. C., Tak, K.-U., Lee, S. M., Lim, C., & Lee, D. (2026) · Nutrients · doi:10.3390/nu18213557
Wu, Y., Guo, C., Li, X., Cheng, J., & Ban, Q. (2026) · Ultrasonics Sonochemistry · doi:10.1016/j.ultsonch.2026.108143
Metadata
- Authors
- Leiphrakpam, P., & Are, C.
- Affiliations
- University of Nebraska Medical Center (US)
- Corresponding author
- Leiphrakpam, Premila
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2024-03-09
- Volume
- 25
- Issue
- 6
- Pages
- 3178
- ISSN
- 1422-0067 (ISSN-L)
- PMC
- PMC10970097
- OpenAlex
- W4392661434
- Cited by
- 193
- References
- 144
- Citations by year
- 2026: 82 · 2025: 82 · 2024: 29
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- International Journal of Molecular Sciences (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Keywords
- colorectal cancer, PI3K/AKT/mTOR pathway, targeted therapy, drug resistance, tumor heterogeneity, metastasis, PI3K inhibitors, AKT inhibitors, mTOR inhibitors, combination therapy
- MeSH terms
- Phosphoinositide-3 Kinase Inhibitors, Humans, Colorectal Neoplasms, Signal Transduction, Phosphatidylinositol 3-Kinases, Proto-Oncogene Proteins c-akt, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.